Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins.
Amprenavir
Antiviral drugs
COVID-19
Darunavir
Enzymes
Non-structural proteins
Rimantadine
SARS-CoV-2
Saquinavir
Journal
Journal of biological research (Thessalonike, Greece)
ISSN: 1790-045X
Titre abrégé: J Biol Res (Thessalon)
Pays: Greece
ID NLM: 101248115
Informations de publication
Date de publication:
04 Aug 2021
04 Aug 2021
Historique:
received:
08
04
2020
accepted:
14
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been deciphered and possible drug target trials are on the way. The present study was aimed to analyze Non-Structural Proteins that include conserved enzymes of SARS-CoV-2 like papain-like protease, main protease, Replicase, RNA-dependent RNA polymerase, methyltransferase, helicase, exoribonuclease and endoribonucleaseas targets to all known drugs. A bioinformatic based web server Drug ReposeER predicted several drug binding motifs in these analyzed proteins. Results revealed that anti-viral drugs Darunavir,Amprenavir, Rimantadine and Saquinavir were the most potent to have 3D-drug binding motifs that were closely associated with the active sites of the SARS-CoV-2 enzymes . Repurposing of the antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir to treat COVID-19 patients could be useful that can potentially prevent human mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Novel Coronavirus disease 2019 or COVID-19 has become a threat to human society due to fast spreading and increasing mortality. It uses vertebrate hosts and presently deploys humans. Life cycle and pathogenicity of SARS-CoV-2 have already been deciphered and possible drug target trials are on the way.
RESULTS
RESULTS
The present study was aimed to analyze Non-Structural Proteins that include conserved enzymes of SARS-CoV-2 like papain-like protease, main protease, Replicase, RNA-dependent RNA polymerase, methyltransferase, helicase, exoribonuclease and endoribonucleaseas targets to all known drugs. A bioinformatic based web server Drug ReposeER predicted several drug binding motifs in these analyzed proteins. Results revealed that anti-viral drugs Darunavir,Amprenavir, Rimantadine and Saquinavir were the most potent to have 3D-drug binding motifs that were closely associated with the active sites of the SARS-CoV-2 enzymes .
CONCLUSIONS
CONCLUSIONS
Repurposing of the antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir to treat COVID-19 patients could be useful that can potentially prevent human mortality.
Identifiants
pubmed: 34344455
doi: 10.1186/s40709-021-00149-2
pii: 10.1186/s40709-021-00149-2
pmc: PMC8331326
doi:
Types de publication
Journal Article
Langues
eng
Pagination
18Informations de copyright
© 2021. The Author(s).
Références
Protein Sci. 2020 Jul;29(7):1596-1605
pubmed: 32304108
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001169
pubmed: 16625539
AIDS Rev. 2017 Apr - Jun;19(2):105-112
pubmed: 28664942
Nat Commun. 2019 May 28;10(1):2342
pubmed: 31138817
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
Sci Rep. 2015 Dec 22;5:18555
pubmed: 26692118
Front Microbiol. 2020 Sep 29;11:587317
pubmed: 33133055
Nucleic Acids Res. 2017 Jul 3;45(W1):W315-W319
pubmed: 28459991
J Virol. 2020 Nov 9;94(23):
pubmed: 32938769
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9436-41
pubmed: 26159422
Acta Pharm Sin B. 2020 May;10(5):766-788
pubmed: 32292689
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Sci Adv. 2021 Feb 5;7(6):
pubmed: 33547084
Antimicrob Agents Chemother. 2004 Dec;48(12):4855-63
pubmed: 15561867
Sci Rep. 2018 Jul 11;8(1):10438
pubmed: 29992979
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Pharmacol Res. 2020 Jul;157:104826
pubmed: 32325127
Int J Mol Sci. 2020 Oct 06;21(19):
pubmed: 33036230
Sci Rep. 2015 May 27;5:10517
pubmed: 26012849
Bioinformation. 2010 Jan 20;4(7):295-9
pubmed: 20978602
Front Mol Biosci. 2020 Dec 17;7:605236
pubmed: 33392262
Nat Commun. 2020 Jul 24;11(1):3717
pubmed: 32709887
Nature. 2020 Aug;584(7819):154-156
pubmed: 32438371
J Chem Inf Model. 2005 Mar-Apr;45(2):300-8
pubmed: 15807491
iScience. 2021 Jan 22;24(1):101903
pubmed: 33319167
Viruses. 2017 Sep 28;9(10):
pubmed: 28956865
Signal Transduct Target Ther. 2020 Jul 29;5(1):131
pubmed: 32728018
Protein J. 2020 Jun;39(3):198-216
pubmed: 32447571
Biochemistry. 2020 Jul 21;59(28):2608-2615
pubmed: 32578982
Mol Biomed. 2020;1(1):5
pubmed: 34765992
J Am Chem Soc. 2020 Oct 14;142(41):17425-17433
pubmed: 32933245
Viruses. 2009 Dec;1(3):1110-36
pubmed: 21994585
Nucleic Acids Res. 2021 Jun 4;49(10):5956-5966
pubmed: 33999154
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Travel Med Infect Dis. 2021 Mar-Apr;40:101989
pubmed: 33578045
Nat Struct Mol Biol. 2020 Oct;27(10):959-966
pubmed: 32908316
Science. 2020 May 15;368(6492):779-782
pubmed: 32277040
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Nat Commun. 2021 Jan 27;12(1):636
pubmed: 33504779
Nucleic Acids Res. 2019 Jul 2;47(W1):W350-W356
pubmed: 31106379
Sci Rep. 2020 Mar 11;10(1):4481
pubmed: 32161317
Lancet. 2021 Jan 9;397(10269):72-74
pubmed: 33306990
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790
pubmed: 32280433
J Mol Graph Model. 2007 Nov;26(4):720-7
pubmed: 17543558
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Lancet Microbe. 2021 Jul;2(7):e279-e280
pubmed: 33899038
PeerJ. 2020 Sep 18;8:e9965
pubmed: 32999768
Vaccines (Basel). 2021 Apr 01;9(4):
pubmed: 33916222
Methods Mol Biol. 2015;1282:1-23
pubmed: 25720466
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088